Healthcare Industry News: Tanox
News Release - April 18, 2016
AnaptysBio Appoints Dr. Matthew Moyle As Chief Scientific OfficerSAN DIEGO, April 18, 2016 -- (Healthcare Sales & Marketing Network) -- AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology, today announced the appointment of Matthew Moyle, Ph.D. as Chief Scientific Officer. Dr. Moyle will be responsible for the discovery and early development of therapeutic antibodies generated using AnaptysBio's proprietary SHM-XEL platform.
"We are pleased to welcome Matthew to AnaptysBio and look forward to his contribution in advancing our proprietary pipeline," said Hamza Suria, President & CEO of AnaptysBio. "Matthew brings extensive experience in antibody discovery and has successfully led early development of biologics across a range of therapeutic areas. Matthew's mandate is to continue expanding AnaptysBio's pipeline by leveraging our proprietary platform technology to discover first-in-class antibodies against emerging targets in inflammation and immuno-oncology."
"I look forward to working with the AnaptysBio team to leverage their proprietary antibody discovery platform in finding novel solutions for patients suffering from debilitating illnesses," said Dr. Moyle. "With the recent advancement of multiple AnaptysBio-generated antibodies to the clinic, the company is well-positioned to expand its inflammation and immuno-oncology antibody pipeline."
Dr. Moyle joins AnaptysBio with more than 25 years of industry experience in discovery and development of biologic therapeutics. Most recently, Dr. Moyle served as Vice President of Biotherapeutics at Boehringer Ingelheim Pharmaceuticals, Inc. where he chaired Boehringer Ingelheim's International NBE Council. Prior to that, Dr. Moyle was Senior Vice President R&D and CSO of Theraclone Sciences, Inc. and Vice President Research of Tanox, Inc., where he led the design and development of monoclonal antibody therapeutic candidates, several of which are currently undergoing clinical development at Roche, Novartis and Gilead. Before Tanox, Dr. Moyle served in various positions at Amgen, Corvas and Genentech. He earned a Ph.D. and B.Sc. in Biochemistry at the University of Toronto.
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company's proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody (ANB020) for the treatment of asthma and peanut allergy, its anti-IL-36R antibody (ANB019) for the treatment of generalized pustular psoriasis and palmo-plantar pustulosis, and a portfolio of checkpoint agonist antibodies for the treatment of severe T-cell driven orphan inflammatory conditions. AnaptysBio's antibody pipeline has been developed using its proprietary SHM-XEL platform, which has pioneered the use of in vitro somatic hypermutation for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of prior antibody technologies. AnaptysBio has also developed multiple therapeutic antibodies in partnership with Celgene and TESARO, including an anti-PD-1 antibody (TSR-042) currently under clinical development.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.